JP2009530413A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530413A5
JP2009530413A5 JP2009501667A JP2009501667A JP2009530413A5 JP 2009530413 A5 JP2009530413 A5 JP 2009530413A5 JP 2009501667 A JP2009501667 A JP 2009501667A JP 2009501667 A JP2009501667 A JP 2009501667A JP 2009530413 A5 JP2009530413 A5 JP 2009530413A5
Authority
JP
Japan
Prior art keywords
optionally substituted
composition
methyl
adenosine receptor
trihydropurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009501667A
Other languages
English (en)
Japanese (ja)
Other versions
JP5250848B2 (ja
JP2009530413A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/064182 external-priority patent/WO2007109547A2/en
Publication of JP2009530413A publication Critical patent/JP2009530413A/ja
Publication of JP2009530413A5 publication Critical patent/JP2009530413A5/ja
Application granted granted Critical
Publication of JP5250848B2 publication Critical patent/JP5250848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009501667A 2006-03-17 2007-03-16 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法 Active JP5250848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78357506P 2006-03-17 2006-03-17
US60/783,575 2006-03-17
PCT/US2007/064182 WO2007109547A2 (en) 2006-03-17 2007-03-16 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012268193A Division JP2013049719A (ja) 2006-03-17 2012-12-07 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法

Publications (3)

Publication Number Publication Date
JP2009530413A JP2009530413A (ja) 2009-08-27
JP2009530413A5 true JP2009530413A5 (enExample) 2011-03-03
JP5250848B2 JP5250848B2 (ja) 2013-07-31

Family

ID=38514256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009501667A Active JP5250848B2 (ja) 2006-03-17 2007-03-16 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法
JP2012268193A Pending JP2013049719A (ja) 2006-03-17 2012-12-07 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012268193A Pending JP2013049719A (ja) 2006-03-17 2012-12-07 Ａ２ｂアデノシン受容体拮抗物質を用いる肝疾患の予防および処置の方法

Country Status (14)

Country Link
US (4) US7795268B2 (enExample)
EP (1) EP1996201A2 (enExample)
JP (2) JP5250848B2 (enExample)
KR (1) KR101428113B1 (enExample)
CN (1) CN101405003B (enExample)
AU (1) AU2007227021B2 (enExample)
CA (2) CA2646333C (enExample)
IL (1) IL194158A0 (enExample)
MX (1) MX2008011828A (enExample)
NO (1) NO20083968L (enExample)
NZ (1) NZ571324A (enExample)
RU (1) RU2457842C2 (enExample)
WO (1) WO2007109547A2 (enExample)
ZA (1) ZA200807894B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
RU2357969C2 (ru) * 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
MX2007004373A (es) 2004-10-15 2007-08-08 Cv Therapeutics Inc Metodo para prevenir y tratar el remoldeo de las vias respiratorias e inflamacion pulmonar utilizando antagonistas de receptor adenosina a2b.
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
EP2301937A1 (en) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
CN101479290A (zh) * 2006-06-27 2009-07-08 比奥维特罗姆上市公司 新的2′,3′-亚甲基缩醛腺苷前药用作腺苷受体激动剂的前药
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20090208550A1 (en) * 2007-10-26 2009-08-20 Cronstein Bruce N Methods and compositions for treating hepatic diseases
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
EP2405917B1 (en) 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
US20140142113A1 (en) * 2012-11-09 2014-05-22 Michael W. Burnet Method of treating inflammatory diseases using adenosine 2b receptor antagonists
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
WO2016129760A1 (ko) * 2015-02-13 2016-08-18 한국과학기술원 Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
KR101666605B1 (ko) 2015-02-13 2016-10-18 한국과학기술원 TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
EP3368064B1 (en) 2015-10-29 2021-05-19 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of anti-cancer chemotherapy
KR102852334B1 (ko) 2016-02-10 2025-09-01 웨이크 포리스트 유니버시티 헬스 사이언시즈 간 섬유화의 모델 시스템 및 그의 제조 및 사용 방법
KR101709307B1 (ko) * 2016-10-31 2017-02-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
EP3634417B1 (en) * 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
EP3675856A4 (en) 2017-08-31 2021-04-14 Corvus Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING THE A2B ADENOSINE RECEPTOR AND A2A ADENOSINE RECEPTOR
CN112218867B (zh) 2018-03-05 2023-11-21 泰昂治疗公司 腺苷受体拮抗剂及其用途
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
JP7394831B2 (ja) * 2018-07-27 2023-12-08 アーカス バイオサイエンシズ インコーポレイティド ピリドンａ２ｒアンタゴニスト
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
NZ532816A (en) 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2004086052A2 (en) 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP2301937A1 (en) 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
WO2007109547A2 (en) 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Similar Documents

Publication Publication Date Title
JP2009530413A5 (enExample)
RU2008137279A (ru) Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина а2в
CN103096881B (zh) 含有具有不愉快味道的药物的膜制剂
RU2404750C2 (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
JP2022009090A5 (enExample)
JP2018507914A5 (enExample)
JP2010530376A5 (enExample)
RU2018133298A (ru) Способы применения агонистов fxr
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
JP2007536311A5 (enExample)
JP2009102342A5 (enExample)
FI3735295T3 (fi) Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon
JP2008540672A (ja) 病状に起因する性的機能不全の治療方法
JP2015524444A5 (enExample)
JP2019503365A5 (enExample)
JP2006523216A5 (enExample)
JP2010503695A5 (enExample)
IL314360A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
ES2973583T3 (es) Regímenes de administración asociados a las formulaciones inyectables de paliperidona de liberación prolongada
JP2013518124A5 (enExample)
JP2015517523A5 (enExample)